This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock KOOL vs. THMO, IMRX, CNTB, AMWL, CLYM, TNYA, SCLX, SKYE, SAVA, and NAKAShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), Immuneering (IMRX), Connect Biopharma (CNTB), American Well (AMWL), Climb Bio (CLYM), Tenaya Therapeutics (TNYA), Scilex (SCLX), Skye Bioscience (SKYE), Cassava Sciences (SAVA), and KindlyMD (NAKA). These companies are all part of the "medical" sector. Cesca Therapeutics vs. Its Competitors ThermoGenesis Immuneering Connect Biopharma American Well Climb Bio Tenaya Therapeutics Scilex Skye Bioscience Cassava Sciences KindlyMD ThermoGenesis (NASDAQ:THMO) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media favor THMO or KOOL? In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Cesca Therapeutics'average media sentiment score. Company Overall Sentiment ThermoGenesis Neutral Cesca Therapeutics Neutral Which has higher valuation & earnings, THMO or KOOL? ThermoGenesis has higher earnings, but lower revenue than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioThermoGenesis$9.61M0.00-$17.98M-$5.14N/ACesca Therapeutics$9.67M3.07-$39.72M-$3.60-3.41 Is THMO or KOOL more profitable? ThermoGenesis has a net margin of 0.00% compared to Cesca Therapeutics' net margin of -98.84%. ThermoGenesis' return on equity of 0.00% beat Cesca Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ThermoGenesisN/A N/A N/A Cesca Therapeutics -98.84%-77.30%-37.75% Do insiders & institutionals believe in THMO or KOOL? 5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 3.1% of Cesca Therapeutics shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 68.9% of Cesca Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, THMO or KOOL? ThermoGenesis has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. SummaryThermoGenesis beats Cesca Therapeutics on 8 of the 10 factors compared between the two stocks. Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.65M$1K$5.76B$9.65BDividend Yield0.50%N/A3.91%4.09%P/E Ratio-3.41N/A30.7825.12Price / Sales3.070.00456.64116.46Price / CashN/AN/A25.2228.45Price / Book3.95N/A9.375.95Net Income-$39.72M-$17.98M$3.26B$265.46M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$12.27-0.1%N/A+16.9%$29.65M$9.67M-3.4153THMOThermoGenesisN/AN/AN/A-99.9%$1K$9.61M0.0040IMRXImmuneering3.5689 of 5 stars$3.25+1.2%$13.25+307.7%+239.8%$115.51M$320K-1.6660Earnings ReportGap UpCNTBConnect Biopharma3.4483 of 5 stars$2.27+10.7%$7.00+208.4%+73.0%$113.90M$26.03M0.00110Positive NewsShort Interest ↓Analyst RevisionAMWLAmerican Well2.9584 of 5 stars$7.10-1.0%$9.17+29.1%-15.9%$111.92M$254.36M-0.881,040CLYMClimb Bio3.5353 of 5 stars$1.61-2.4%$9.00+459.0%N/A$111.50MN/A-0.689News CoverageEarnings ReportGap UpTNYATenaya Therapeutics3.0275 of 5 stars$0.76+11.1%$6.25+725.6%-56.4%$111.02MN/A-0.79110Gap UpSCLXScilex2.1906 of 5 stars$17.67+11.7%$455.00+2,475.0%-55.0%$109.97M$56.59M-0.6180Earnings ReportSKYESkye Bioscience1.7339 of 5 stars$3.25-7.4%$16.60+410.8%-27.3%$108.77MN/A-3.0711SAVACassava Sciences2.3056 of 5 stars$2.32+3.1%$2.00-13.8%-92.0%$108.69MN/A-1.5530Earnings ReportNAKAKindlyMDN/A$11.09-22.3%N/AN/A$108.62M$2.72M-12.90N/ANews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies THMO Alternatives IMRX Alternatives CNTB Alternatives AMWL Alternatives CLYM Alternatives TNYA Alternatives SCLX Alternatives SKYE Alternatives SAVA Alternatives NAKA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOOL) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access